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•

•

•

To identify what the regulations allow with regards to consent.
To identify which type of consent is best for various types of
studies. To understand when HIPAA, conflicts of interest and reconsent apply to a study’s consent process.

To delineate criteria in determining what type of data and safety
monitoring is best for a study. To understand what information
is necessary in developing a data monitoring plan for a study.
To know the criteria used in determining if an investigational
drug or device exists. To understand the requirements of IND or
IDE holders. To know when one is the IND or IDE holder. To
understand FDA processes regarding INDs and IDEs.






Consent including Assent
Data Monitoring
Investigational Drugs and Devices
Placebo



When thinking about consent, think about
the entire process:


Will our initial contact be through recruitment
material?


What form will this take?

Who will obtain consent
 Where
 How long will we give the participant to think
about whether or not he/she wants to
participate?
 Will we re-consent? How and when?




What is an appropriate consent type for
your study?


Full written consent




Oral or telephone consent or information sheet




All 8 elements needed?

Waiver of Written Consent

Waiver of consent (no consent obtained)


No follow-up

1.

–

What is your population?
•

•

–

•

Native English speakers or Non-English speakers

For non-English speakers do you have translators? Are
you prepared to pay to have the consent and other
materials translated?
Is there a chance non-English speakers will ever be
enrolled? Are you prepared to handled this?

Capable of providing consent or will a legally
authorized representative be needed as in the case
of minors or cognitively impaired
What type of assent process will be used?

2. What is best for your study design?
–

•

•

–
•

–
•

What will best inform the participants?

Complicated study design probably needs a written
consent document
You can propose more than one consent process for
your study, if appropriate given your populations.

Will there possibly be follow-up in the future?

Obtain consent. Do not ask for a waiver of consent.

What will help keep anonymity of participants?
No participant identifiers are being collected.

–

May want to use an information sheet (Waiver of Written
Consent available to non-FDA regulated studies)

•

Is your study FDA regulated?
–

–

Any use of a drug (a pharmaceutical preparation), other than
the use of a marketed drug in the course of medical practice.
Any protocol where a drug is administered as part of the
protocol is FDA “research.”
•

For example, the protocol says all individuals will take 325 mg of
aspirin. The exception is when the drug is up to physician
discretion. For example, the protocol states: “Subjects who get a
headache may take an aspirin at the direction of their physician.”
This is without regard to “research” intent as defined by DHHS
regulations. Administration of any non-approved drug (for any
purpose – investigational or treatment) is “research” as defined by
FDA. Use of a FDA-approved drug for a non-approved purpose is
ordinarily classified as research. This includes “off-label” uses for
research purposes.

•

Any activity undertaken to determine the safety or efficacy of a medical
device.
–

•

A comparison of two diagnostic imaging modalities is FDA “research”.
–

•

•

For example, oncology studies that involve external beam radiation are FDA
“research” because they evaluate the safety and effectiveness of a device
(radiation therapy machine) for treating a specific cancer.
For example, all patients getting a CT scan will also undergo diagnostic
ultrasound and the results of the two will be compared.

Any activity whose results will be submitted to or held for inspection by
FDA in support of a marketing permit.
Any collection of data that is supported by a drug or device company
should be assumed to be FDA “research” unless the sponsor has
indicated in writing that the data will not be provided to FDA and will
not be held for inspection by FDA.

•

You need to use full written consent.
–

Include all 8 elements of consent
•
•

Purpose
Participation
–

•
•

Costs/Payments
Risks
–

•
•
•

Include the appropriate injury language

Benefits
Alternatives
Confidentiality
–

•

include a description of investigational procedures

Include HIPAA authorization language

Contacts

•

Your study is FDA regulated but it will qualify
for expedited review,
•

therefore it most likely will receive a minimal risk
designation

and the study involves no procedures for which
written consent is normally required outside of
the research context.
–

Is a Waiver of Written Consent appropriate for your
study?
•

Examples: telephone consent, oral consent, information
sheet (consent document with no signature lines)





Normally all 8 elements of consent are
included.
WU includes 10 elements of consent in its
biomedical consent template and 8 elements
in its behavioral template, designed for
minimal risk studies.


Why?


Optional elements are included in the biomedical
consent template such as the injury language which is
not needed in minimal risk research

•

Is your study a longitudinal study or does
your study involve populations that may
reach age of maturation or whose cognitive
abilities may decrease over time?
–

Re-consent procedures may be appropriate for
your study.
•

Re-consent can take many forms: signing another
consent document, a verbal conversation that is
noted in the research record, a consent addendum,
information sent via an information sheet/letter to
the participant.







Are you conducting the research at the
medical school, or at Student Services or
Psychological Services on the Danforth
campus?
Are you getting information out of, or
putting information into a medical chart?
If yes to either, HIPAA applies.



WU puts its HIPAA authorization language
into the consent document under
Confidentiality.

Delineate what PHI will be collected, from
where, who will have access, who will it be
shared with, and in what format.
 If there are restrictions for contact those should
be listed.
 Include the Notice of Privacy box for treatment
studies




Will participants possibly be contacted in
the future to participate in other studies?




Will need permission for future contact if HIPAA
applies to your study.

Will you want to access the data collected in
this study for future studies?


Will need authorization to share data if HIPAA
applies to your study.

•

•

•

•

Disclosure of any financial conflicts of interest
that a study team member may have.
Costs that may be incurred by the research
participants.
Payments given to participants.

A statement regarding death if possible for the
study.

•

•

Radiation exposure language, if applicable
Authorization to send PHI via e-mail
–
–

•

•

WU discourages sending PHI via e-mail
Read and know HIPAA Security Policy #17 found on the
HIPAA website at http://hipaa.wustl.edu

Language for Siteman Cancer Center, if applicable

Center for Applied Sciences language when any of
their units are being used: Clinical Trials Unit,
Pediatric Research Unit, Clinical Research Unit.





Consent is a process and begins with the
initial participant contact, usually during
recruitment, and continue throughout the
study.

Regardless of the consent process utilized,
federal guidelines tell us that the language
used in materials going to research
participants should be understandable to
the target population.



Determine the best assent process or
processes for your population.


Options:

Waiver of Assent
 Oral Assent






Written Assent




Script or outline

Separate assent document or have the individual sign an
assent line placed on the consent document

You may propose more than one assent process for your study, this is
especially important when a variety of ages are recruited.






Monitor adverse events for trends
Look at safety data to protect the
participants

Consider the size and risks of the study,
when determining the right plan for your
study.



How much risk is involved in your study.






Is there prior safety data that might suggest a
higher volume of adverse events?
Current literature.
Is there something in the study design that
would suggest that this study would place
individuals at greater risk of harm?

Studies with more risk require more oversight.



Options:

PI or research team member monitors the
adverse events, for trends, alone.
 A group of research team members monitor the
adverse events for trends.
 One or more individuals outside the research
team monitor the study for trends.
 A data monitoring committee is formed:




field expert, unaffiliated member, statistician


Can use groups already in place with the distribution above.





All adverse events, regardless of whether or
not they are submitted to the IRB.
Other types of safety data depending on the
study:
Efficacy information
 Drug experiences in other studies
 Toxicities
 Literature that gives previous or current
experiences with the drug, device, or agent






How often the data will be looked at.
What types of reports will be generated.
What the stopping criteria should be


Under what conditions would you stop the
study?


A statistician can help define these.



You must also consider:


How will you obtain safety data from the other
sites?




Set up agreements to ensure that you receive this
data.

What requirements will you use for reporting?


If WU is the coordinating center, consider using the
HRPO “What Should I Report to HRPO “ guideline in
setting up reporting requirements



On the HRPO website under Model Forms,
http://hrpo.wustl.edu.

SAMPLE DATA MONITORING PLAN
For multi-center studies, your data monitoring plan should describe monitoring for the entire study as well as monitoring at
WU.
Based on size and risks of the study, consider
•a plan where more than one individual monitors the study
•a plan with an independent monitor,
•a Data Monitoring Committee,
•individual(s) independent of sponsor and study.
•Study Monitoring.
Who will monitor the study for safety at WU? For multi-center studies, who will monitor study-wide?
_____ (PI, independent monitor, Research team, MD, PhD, biostatistician, BSN, RPh, etc) will monitor the study in accordance with
the HRPO guideline titled “What Should I Report to HRPO?”.
•Reporting.
All reportable events will be sent in accordance with timeframes specified in the HRPO guideline titled, “What Should I Report to
HRPO?”.
Other reports that will be generated are________________. (Indicate if there will be other reports. Examples: safety reports, interim
data analysis reports, summary reports, etc. What reports will be generated study-wide, for multi-center studies?)
These other reports will be sent to the HRPO (IRB) ________________________. (Indicate frequency for all reports generated. This
includes those generated at WU and those generated study-wide for multi-center studies. Frequencies could include: annually, semiannually, on an occurrence basis, after X number of weeks/months, after X number of subjects enrolled, after X number of adverse
events, etc.)
______ will be reported to the sponsor. (Indicate which reports are sent to the sponsor. This includes reports generated at WU as
well as those generated study-wide, for multi-center studies. All reports sent to the IRB must be sent to the sponsor, if one exists.)
Should there be an event or series of events that occur that increases the risks to the participants, the “following steps” will be
taken_________________________ (Examples: conduct an investigation, modify the protocol, suspend the study, close the study,
etc. Include examples that occur at WU as well as those that could occur study-wide for multi-center studies.) and will be reported to
___________(Indicate who will receive the reports, e.g. IRB, sponsor, independent monitor, etc.) within ______ (Indicate the
timeframe in which reports will be sent, eg. immediately, within 7 calendar days, within 24 hours, etc. At a minimum reporting
timeframes to the IRB should be in accordance with the HRPO guideline, “What Should I Report to HRPO?”)

1. Changes in the status of the study due to safety concerns (such as a
suspension or closure of enrollment)
2. Adverse Events:
A. Internal Adverse Events and External Adverse Events occurring in the
same study if they are:



Serious (regardless of expectedness or relatedness) or;
Unexpected and reasonably related (regardless of seriousness)

B. External Adverse Events occurring in a different study if the adverse
event places the participant(s) at a greater risk of harm than was
previously known or recognized

3. Unanticipated Adverse Device Experiences (UADEs)
4. Protocol Exceptions (formerly Deviations or planned deviation)

5. Protocol Errors (formerly Violations/Errors or unplanned deviation)
6. Complex Complaints
7. Breaches of Confidentiality
8. Audit/Inspection/Inquiry
9. Participant Incarceration
10. New Information (Safety Monitoring, Data Safety Monitoring Board
(DSMB) or Data Monitoring Committee (DMC) reports, interim analysis
reports, progress reports or any event or new information that
suggests the research places participants or others at a greater risk of
harm than was previously known or recognized)
For more information see “What Should I Report to HRPO?” at
http://hrpo.wustl.edu under Guidelines

1.

2.

3.

How many here conduct investigator initiated
studies that use investigational drugs or
devices?

How many have applied for the IND or IDE for
their study team or themselves?

How many prepare the drug or manufacture the
device?




Is the drug investigational?
Is the drug FDA approved but being used in
an investigational fashion? (e.g. off label)
The drug is investigational.
 You need to apply to the FDA for an
Investigational New Drug (IND) number.
 If you are not following a sponsor’s guidelines,
you must abide by the WU Investigational
Drug/Device Accountability Policy
















The drug is FDA-approved; AND
The use is not intended to be reported to the FDA in support of a new
indication for use or to support any other significant change in labeling of
drug; AND
The use is not intended to support a significant change in the advertising of the
product; AND
The use does not involve a route of administration or dosage level, use in a
subject population, or other factor that significantly increases the risks (or
decreases the acceptability of the risks) associated with the use of the drug
product; AND
The study is conducted in compliance with the requirements for IRB review
and informed consent (21 CFR parts 56 & 50); AND
The study is conducted in compliance with the requirements concerning the
promotion and sale of drugs (21 CFR 312.7); AND
The study does not intend to invoke 21 CFR 50.24 (Emergency Use).



21 CFR 312, subpart D

Responsible for selecting a qualified
investigator
 Provide the investigator with the key
information needed to conduct the study.
 Ensure proper monitoring of the investigation
 Ensure that the investigation is conducted in
accordance with the general investigational
plan and protocols contained in the IND






Maintain an effective IND with respect to the
investigations
Ensure that FDA and all participating
investigators are promptly informed of
significant new adverse effects or risks with
respect to the drug.



Go to the FDA website for directions:

http://www.fda.gov/cder/forms/1571-1572-help.html




Complete FORM FDA 1572 for sponsorinvestigators
Complete FORM FDA 3674 to register with
ClinicalTrials.gov


The Food and Drug Administration Amendments Act of 2007 (FDAAA) (Public Law
110-85) was enacted on September 27, 2007. Title VIII of FDAAA added new Section
402(j) to the Public Health Service Act (42 USC § 282(j)) and expanded the current
database known as ClinicalTrials.gov to include mandatory registration and
reporting of results for applicable clinical trials of human drugs (including biological
products) and devices.





Medical devices include surgical lasers, wheelchairs,
sutures, pacemakers, vascular grafts, intraocular
lenses, and orthopedic pins. A longer list can be
found in the HRPO Investigational Drug (IND) and
Investigational Device Exemption (IDE) Guideline
on the HRPO website, http://hrpo.wustl.edu under
Guidelines
Medical devices also include diagnostic products
such as in vitro diagnostic reagents and test kits
such as pregnancy test kits and imaging systems
such as MRI.





The device is not FDA approved for the
indication.
The FDA approved device has been altered
or a biologic has been added.
If yes to either. The device is investigational.
 Is the device Significant Risk (SR)? If yes, an
Investigational Device Exemption (IDE) is
needed.






Given a Significant risk device
determination by an IRB.

To obtain a FDA determination, you must
apply to FDA



21 CFR 812.40








Responsible for selecting a qualified investigator
Provide the investigator with the key information
needed to conduct the study.
Ensure proper monitoring of the investigation
Ensure that IRB review and approval are obtained
Submit an IDE application to FDA
Ensure that any reviewing IRB and FDA are
promptly informed of significant new information











Application
Investigational Plan
Report of prior investigations
FDA action on the application: approval or
disapproval
Supplemental applications: all changes to the
investigational plan require prior approval
Treatment use of the investigational device
Confidentiality of data and information



21 CFR 812, Investigational Device
Exemptions, covers the procedures for the
conduct of clinical studies with medical
devices including application,
responsibilities of sponsors and
investigators, labeling, records, and reports.



“A sponsor shall, upon request by a
reviewing IRB or FDA, provide accurate,
complete, and current information about
any aspect of the investigation.”










Unanticipated adverse device effects
Withdrawal of IRB or FDA approval
Current investigator list
Progress reports
Recall and device disposition
Final report
Informed consent
Significant risk device determinations



21 CFR 812 covers 3 types of devices:






Significant Risk

Non-significant Risk
Exempt



A significant risk device poses a “potential for serious
risk to the health, safety, or welfare of a subject.” Such
devices may only be studied under an Investigational
Device Exemption (IDE) granted by the FDA. A device is
SR (and requires an IDE) if it:







is intended as an implant, or
is purported or represented to be for a use in supporting or
sustaining human life, or
is for a use of substantial importance in diagnosing, curing,
mitigating, or treating disease, or otherwise preventing
impairment of human health; or
otherwise presents a potential for serious risk to the health, safety,
or welfare of a subject.



IRB makes this determination. In doing so,
the IRB needs the following:

Description of why the device is not significant
risk
 The proposed use of the device, as well as any
protocol related procedures and tests
 Additional information regarding the device
from the sponsor, if needed.




Exempt studies still need IRB review
Examples: Humanitarian Use Devices
 Those with a 510K submission




Intended to benefit patients by treating or
diagnosing a disease or condition that affects fewer
than 4,000 individuals in the United States per year.





affects a small patient populations.
A Humanitarian Device Exemption enables the provision of
humanitarian use devices (HUDs) in the population described
above faster than the traditional FDA approval process.

An approved HDE authorizes marketing of the HUD.
However, a HUD may only be used after IRB approval
has been obtained for the use of the device for the
FDA approved indication.


The labeling for a HUD must state that the device is a
humanitarian use device and that, although the device is
authorized by Federal Law, the effectiveness of the device for
the specific indication has not been demonstrated.







Some type of consent is still needed.

21 CFR 814.124 requires IRB review and
approval.

This device is not considered investigational
as FDA approval of the Humanitarian Device
Exemption is a marketing approval.







Most stringent type of device marketing
application
For a PMA to be approved, FDA must
determine that sufficient valid scientific
evidence exists to assure that the device is
safe and effective for its intended use(s).
For more information, go to
www.fda.gov/cdrh/devadvice



During the FDA review of the premarket
notification, the device remains
investigational and is still subject to:

IRB review and regulations
 Informed consent processes
 Safeguards for research participants, including
additional safeguards for vulnerable
populations such as children
 IDE regulations




Implications for being the IND or IDE
holder:
You function as the sponsor.
 You will have the responsibilities of the
investigator and the sponsor.




You are responsible for:


All aspects of the clinical study including:


Communication with FDA




Safety reports, annual reports, protocol amendments etc.

Ensuring proper infrastructure is in place to perform
the clinical investigation


Staff training, development of study, SOPs, proper informed
consent process, protocol adherence, adverse event
reporting, maintenance of regulatory files, drug and/or
device accountability records, maintenance of complete
case histories, etc.



You are also responsible for:




Monitoring the conduct and progress of the study

Reviewing and evaluating any information relevant
to the safety of the drug/biologic or device



Which include:


Ensuring the study is conducted according to

the signed investigational statement (eg. Form
1572)
 The investigational plan
 Applicable regulations for informed consent
IRB approval is met
Rights, welfare, and safety of participants in the study are
protected
Ensuring that all other responsibilities listed in the
applicable FDA regulations are met











FDA should get back to you within 30 days
regarding its decision
The drug/device must be listed as
“investigational” in the consent document.



If you prepare the drug or manufacture the
device, you must abide by Good
Manufacturing Practices.





Good Manufacturing Practice or GMP (also referred to as 'cGMP' or
'current Good Manufacturing Practice') is a term that is recognized
worldwide for the control and management of manufacturing and
quality control testing of foods, pharmaceutical products, and medical
devices.

In the US, the phrase "current good manufacturing practice" appears in
501(B) of the 1938 Food, Drug, and Cosmetic Act (21USC351). US
courts may theoretically hold that a drug product is adulterated even if
there is no specific regulatory requirement that was violated as long as
the process was not performed according to industry standards. By
June 2010, the same cGMP requirements will apply to all manufacture
of dietary supplements.[1]







GMP takes the holistic approach of regulating the manufacturing and
laboratory testing environment itself.
An extremely important part of GMP is documentation of every aspect
of the process, activities, and operations involved with drug and
medical device manufacture. If the documentation showing how the
product was made and tested (which enables traceability and, in the
event of future problems, recall from the market) is not correct and in
order, then the product does not meet the required specification and is
considered contaminated (adulterated in the US).
Additionally, GMP requires that all manufacturing and testing
equipment has been qualified as suitable for use, and that all
operational methodologies and procedures (such as manufacturing,
cleaning, and analytical testing) utilized in the drug manufacturing
process have been validated (according to predetermined
specifications), to demonstrate that they can perform their purported
function(s).









GMP for drugs, 21 CFR 210 & 211

GMP for biologics, blood and blood
components, 21 CFR 600 & 606
GMP for devices, 21 CFR 820

GMP for human cells, tissues, cellular and
tissue-based products, 21 CFR 1271

Good Clinical Practices




Good Clinical Practice is an international quality standard that is
provided by International Conference on Harmonisation (ICH), an
international body that defines standards, which governments can
transpose into regulations for clinical trials involving human subjects.

Good Clinical Practice guidelines include protection of human rights as
a subject in clinical trial. It also provides assurance of the safety and
efficacy of the newly developed compounds.



Good Clinical Practice Guidelines include:

standards on how clinical trials should be
conducted,
 define the roles and responsibilities of clinical
trial sponsors,
 Define the roles and responsibilities of the
clinical research investigators,
 Define the roles and responsibilities of the
clinical monitors. (In the pharmaceutical industry monitors are


often called Clinical Research Associates.)









21 CFR 50, Protection of Human Subjects, provides the requirements
and general elements of informed consent;
21 CFR 56, Institutional Review Boards, covers the procedures and
responsibilities for institutional review boards (IRBs) that approve
clinical investigations protocols;
21 CFR 54, Financial Disclosure by Clinical Investigators, covers the
disclosure of financial compensation to clinical investigators which is
part of FDA’s assessment of the reliability of the clinical data.
21 CFR 820 Subpart C, Design Controls of the Quality System Regulation,
provides the requirement for procedures to control the design of the
device in order to ensure that the specified design requirements are
met.



You either abide by the sponsor’s guidelines
for handling or you must abide by the WU
Investigational Drug/Device Accountability
Policy.



Found on the Vice Chancellor for Research
page at

http://research.wustl.edu/PoliciesGuidelines
/Pages/IDDA.aspx



What it specifies;

Receipt and inventory of investigational
drugs/devices
 Storage of investigational drugs/devices
 Dispensing of investigational drugs/devices
 Return or disposal of investigational
drugs/devices


Depending on your study, and if an industry
sponsor is involved, you may be asked to
abide by:
Good Lab Practices
 Good Tissue Practices




E.g. Blood banking, cell suspensions, manufactured
or manipulated in a closed system or allergens
prepared or manipulated in a closed system. Closed
systems are not open to the environment.





Good laboratory practice generally refers to a system of
management controls for laboratories and research
organizations to ensure the consistency and reliability of
results as outlined in the Organisation for Economic Cooperation and Development (OECD) Principles of GLP and
national regulations.

GLP applies to non-clinical studies conducted for the
assessment of the safety of chemicals to man, animals and
the environment. The internationally accepted definition is
as follows:





Good Laboratory Practice (GLP) embodies a set of principles that
provides a framework within which laboratory studies are planned,
performed, monitored, recorded, reported and archived. These studies
are undertaken to generate data by which the hazards and risks to users,
consumers and third parties, including the environment, can be assessed
for pharmaceuticals (only preclinical studies), agrochemicals, cosmetics,
food additives, feed additives and contaminants, novel foods, biocides,
detergents etc.... GLP helps assure regulatory authorities that the data
submitted are a true reflection of the results obtained during the study
and can therefore be relied upon when making risk/safety assessments.
GLP can be confused with the standards of laboratory safety - wearing
appropriate gloves, glasses and clothing to handle materials safely.







Current Good Tissue Practice (cGTP), also known as Good Tissue
Practice (GTP), is a term that is one of the "GxP" requirements derived
from cGMP. The rule was written and is enforced by the U.S. Food and
Drug Administration (FDA), specifically the Center for Biologics
Evaluation and Research.
It is generally used to mean the requirements of section 1271 of
chapter 21 of the US Code of Federal Regulations, though the rule itself
specifies that the GTPs are only subpart D of that section.[1]
The rules cover a broad variety of articles referred to as "HCT/Ps" for
Human Cellular, Tissue, and Tissue-based Products and the regulations
cover more or less any cellular entity taken from a human and
transplanted into another human. There are several exceptions in the
rules for Organ transplants, blood for transfusion, and other articles
which already have established requirements.







The rules are an expansion and revision of the section 1270 of the
same chapter and now cover a larger group of products. The most
controversial products covered in these rules include stem cells and
tissue used in reproductive medicine (assisted reproductive
technology): sperm, oocytes, and embryos.

These rules only cover tissue which has not been significantly
modified. Any major changes will make the product into either a drug
or a medical device, though some of the rules in this section still apply
to human-sourced drugs and medical devices.
The rules only affect products collected after May 25, 2005.

No proven therapy exists
 A proven therapy exists but:


There is compelling and scientifically sound reasons
for its use
 The toxicity of the treatment is such that patients
commonly refuse it
 Patients who receive placebo will not be subject to
any additional risk of serious or irreversible harm
 Denial of active treatment may not pose an increased
risk of death, severe morbidity or disability or severe
discomfort










Participants must be informed that they
may receive a placebo
Any viable alternatives, if applicable
Rationale for using placebo
Duration of time, discomfort, and potential
effects of receiving a placebo
Consequences of delayed active treatment
HRPO Use of Placebo Guideline and Form S



Appropriate submission form


List engaged members of your team

Those under WU auspices need CITI training
 See the Human Subjects Education Policy at
http://www.wustl.edu/policies/humansubjectseduc
ation.html




List engaged sites – Federal Wide Assurance
(FWA) numbers needed. (Form B)


If using community agencies, physicians, etc.


Be aware: We need their FWA number. If they do not have
one, they will need either the FWA or an individual
investigator agreement (IAA).









Protocol with data safety monitoring plan
Consent process with appropriate
documents, outlines, letters, forms,
Grant with salaries blocked out, if WU is the
primary awardee
Recruitment materials, if available
Form T, Financial Conflict of Interest (if
applicable)



Investigational drugs/devices

Form C, IND/IDE includes radioactive drugs,
other biologics and dietary supplements
 IND/IDE number or exemption letter (if
obtained prior to IRB review)
 Description of the device and its intended use, if
applicable
 Any investigational drug brochures or device
pamphlets




This list is not all inclusive. HRPO forms will
guide you to any auxiliary forms or
approvals you may need.
Form E, Minors (0-17 yrs in MO)
 Form P, Research Related Radiation, if
applicable
 Form N, STORED DATA OR TISSUE FOR FUTURE
RESEARCH, RESEARCH INVOLVING
 FORM S, JUSTIFICATION FOR USE OF A PLACEBO




HRPO website, http://hrpo.wustl.edu

Guidelines page:
http://hrpohome.wustl.edu/default.aspx
 Drug/Device Guidelines:
http://hrpohome.wustl.edu/study_team/guidel
ines/drug_device_guidelines.aspx




Vice Chancellor for Research website,
http://research.wustl.edu

